Új-Zéland - angol - Ministry for Primary Industries

bayer new zealand limited - phenmedipham; metamitron; desmedipham; ethofumesate - phenmedipham 60 g/litre; metamitron 200 g/litre; desmedipham 60 g/litre; ethofumesate 60 g/litre - herbicide - herbicide - group c1+n

Új-Zéland - angol - Ministry for Primary Industries

bayer new zealand limited - prothioconazole; bixafen - emulsifiable concentrate - prothioconazole 150 g/litre; bixafen 75 g/litre - fungicide - fungicide

Új-Zéland - angol - Ministry for Primary Industries

bayer new zealand limited - trifloxystrobin; fluopyram - suspension concentrate - trifloxystrobin 250 g/litre; fluopyram 250 g/litre - fungicide - fungicide

Új-Zéland - angol - Ministry for Primary Industries

bayer new zealand limited - fluopyram - suspension concentrate - fluopyram 400 g/litre - nematicide - insecticide

Új-Zéland - angol - Ministry for Primary Industries

bayer new zealand limited - indaziflam - suspension concentrate - indaziflam 500 g/litre - herbicide - herbicide

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salmeterol xinafoate, quantity: 72.5 microgram/actuation (equivalent: salmeterol, qty 50 microgram/actuation); fluticasone propionate, quantity: 100 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta-2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,*initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on "as needed" reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring medication every day (see clinical trials).,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. pavtide is not indicated for the initiation of bronchodilator therapy in copd.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - doxycycline hyclate, quantity: 57.7 mg (equivalent: doxycycline, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; maize starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; macrogol 4000 - infections caused by the following microorganisms: mycoplasma pneumoniae (primary atypical pneumonia); rickettsiae (queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus): chlamydia psittaci (psittacosis); chlamydia trachomatis (lymphogranuloma venereum, trachoma, inclusion conjunctivitis). (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline alone or in combination with topical agents). borreliae (relapsing fever); calymmatobacterium (donovania) granulomatis (granuloma inguinale). infections caused by the following gram-negative microorganisms: vibrio sp. (cholera); brucella sp. (brucellosis, in conjunction with streptomycin); haemophilus ducreyi (chancroid); yersinia pestis (plague); francisella tularensis (tularaemia); bartonella bacilliformis (bartonellosis); bacteroides sp. when penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: treponema pallidum (syphilis); treponema perenue (yaws); neisseria gonorrhoea (see dosage and administration). doxycycline is not the drug of choice in the treatment of any type of staphylococcal infection of infections caused by streptococcus pneumoniae, haemophilus influenzae, streptococcus pyogenes, enterococcus faecalis or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. doxycycline should not be used in these infections unless the organism has been shown to be sensitive. for upper respiratory infections due to group a b-haemolytic streptococci (including prophylaxis of rheumatic fever), penicillin is the usual drug of choice. in acute intestinal amoebiasis doxycycline may be a useful adjunct to amoebicides. in severe acne, doxycycline may be a useful adjunctive therapy. doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by plasmodium vivax. doxycycline is only able to suppress malaria caused by p. vivax. as there are relatively few locations where p. vivax does not co-exist to some extent with p. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example chloroquine. note: the 50mg tablet is not a paediatric formulation.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis a virus antigen, quantity: 720 elisa unit - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; aluminium; polysorbate 20; dibasic sodium phosphate heptahydrate; monobasic potassium phosphate; sodium chloride; potassium chloride; water for injections; acetic acid; leucine; phenylalanine; methionine; lysine hydrochloride; isoleucine; valine; histidine; threonine; tryptophan; alanine; arginine; proline; tyrosine; serine; sodium acetate; dibasic potassium phosphate; magnesium chloride hexahydrate; glycine - havrix is indicated for active immunisation against hepatitis a virus (hav) infection in susceptible subjects at risk of exposure to hav. havrix junior is indicated in subjects aged 2 to 15 years and havrix 1440 is indicated in subjects aged 16 years and older. in areas of low prevalence of hepatitis a, immunisation with havrix is particularly recommended in the following subjects: travellers : persons travelling to areas of intermediate or high endemicity for hepatitis a. these areas include africa, asia, india, the pacific islands, the mediterranean basin, the middle east, central and south america. armed forces : armed forces personnel who travel to higher endemicity areas or to areas where hygiene is poor, have an increased risk of hav infection. persons for whom hepatitis a is an occupational hazard or for whom there is an increased risk of transmission. these include: employees in day-care centres particularly in situations where children have not been toilet trained; teachers and other close contacts of the intellectually disabled; staff and residents of residential facilities for the intellectually disabled; health workers and teachers in remote aboriginal and torres strait islander communities; nursing staff and other healthcare workers in contact with patients in paediatric wards, infectious diseases wards, emergency rooms and intensive care units sewerage workers ; food handlers, since food hygiene procedures and food processing methods are not always adequate to protect from contamination from food handlers. homosexual men : increased incidence of hepatitis a infection among homosexual males suggests that the disease may be sexually transmitted in this group. contacts of infected persons : since virus shedding from infected persons may occur for a prolonged period, active immunisation of close contacts is recommended. the use of vaccine in outbreak control has been shown to be more effective than the use of immunoglobulin. specific population groups known to have a higher incidence of hepatitis a: eg. australian aboriginals, recognised community-wide hav epidemics. individuals with chronic liver disease and recipients of liver transplants, as hepatitis a infections is likely to be more severe in these groups. many injecting drug users will have pre-existing liver disease from hepatitis b or hepatitis c infection. recipients of blood products, such as factor viii eg. haemophiliacs. havrix will not prevent hepatitis infection caused by other agents such as hepatitis b virus, hepatitis c virus, hepatitis d virus, hepatitis e or other pathogens known to infect the liver.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis a virus antigen, quantity: 1440 elisa unit - injection, suspension - excipient ingredients: polysorbate 20; dibasic sodium phosphate heptahydrate; monobasic potassium phosphate; sodium chloride; potassium chloride; water for injections; aluminium hydroxide hydrate; acetic acid; leucine; phenylalanine; methionine; lysine hydrochloride; isoleucine; valine; histidine; threonine; tryptophan; alanine; arginine; proline; tyrosine; serine; sodium acetate; dibasic potassium phosphate; magnesium chloride hexahydrate; glycine - havrix is indicated for active immunisation against hepatitis a virus (hav) infection in susceptible subjects at risk of exposure to hav. havrix junior is indicated in subjects aged 2 to 15 years and havrix 1440 is indicated in subjects aged 16 years and older. in areas of low prevalence of hepatitis a, immunisation with havrix is particularly recommended in the following subjects: travellers : persons travelling to areas of intermediate or high endemicity for hepatitis a. these areas include africa, asia, india, the pacific islands, the mediterranean basin, the middle east, central and south america. armed forces : armed forces personnel who travel to higher endemicity areas or to areas where hygiene is poor, have an increased risk of hav infection. persons for whom hepatitis a is an occupational hazard or for whom there is an increased risk of transmission. these include: employees in day-care centres particularly in situations where children have not been toilet trained; teachers and other close contacts of the intellectually disabled; staff and residents of residential facilities for the intellectually disabled; health workers and teachers in remote aboriginal and torres strait islander communities; nursing staff and other healthcare workers in contact with patients in paediatric wards, infectious diseases wards, emergency rooms and intensive care units sewerage workers ; food handlers, since food hygiene procedures and food processing methods are not always adequate to protect from contamination from food handlers. homosexual men : increased incidence of hepatitis a infection among homosexual males suggests that the disease may be sexually transmitted in this group. contacts of infected persons : since virus shedding from infected persons may occur for a prolonged period, active immunisation of close contacts is recommended. the use of vaccine in outbreak control has been shown to be more effective than the use of immunoglobulin. specific population groups known to have a higher incidence of hepatitis a: eg. australian aboriginals, recognised community-wide hav epidemics. individuals with chronic liver disease and recipients of liver transplants, as hepatitis a infections is likely to be more severe in these groups. many injecting drug users will have pre-existing liver disease from hepatitis b or hepatitis c infection. recipients of blood products, such as factor viii eg. haemophiliacs. havrix will not prevent hepatitis infection caused by other agents such as hepatitis b virus, hepatitis c virus, hepatitis d virus, hepatitis e or other pathogens known to infect the liver.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ciprofloxacin, quantity: 400 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; glucose monohydrate; lactic acid - ciprofloxacin injection for intravenous infusion is indicated for use in the following: 1. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. 2. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems: - lower respiratory tract infections (gram-negative organisms). skin and skin structure. septicaemia. bone and joint. urinary tract. 3. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram positive infections due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiologic agents, additional therapy should be considered.